| Similar Articles |
|---|
 |
ONLINE
Jan/Feb 2002
Elaine N. Cheeseman |
IDdb3: Pharmaceutical Intelligence for the Third Millennium Are you looking for many types of drug pipeline information in one place? Interested in locating current pharmaceutical patent, company, or conference information? Do you need quick and easy access to this information?   |
Information Today
July 30, 2001
Paula J. Hane |
Dialog Makes New Desktop Search Application Available Through Dialog IQ While it has not yet been announced or even rolled out officially to the Dialog sales force, Dialog IQ is now available. Dialog IQ is an easy-to-use desktop application designed for both corporate knowledge workers and inexperienced searchers... |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Information Today
March 15, 2004
Matthew J. McBride |
Dialog Technology Changes Foreshadow Improvements Dialog's recent announcement of a new platform and enhanced interfaces to both Dialog Profound and Dialog NewsRoom provides insight into some changes users can expect from Dialog in 2004/2005 |
The Motley Fool
December 29, 2006
Brian Lawler |
Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note. |
Information Today
May 7, 2001
Barbara Quint |
Dialog Sets 2001 Strategy in Flurry of Announcements After months of comparative silence, Dialog Corp., a subsidiary of Thomson Corp., has published a spate of announcements reflecting its new strategy and plans for 2001... |
Information Today
May 30, 2000
Barbara Quint |
Dialog Gets Smart with Outsmart Company Profiles Searchers will soon be able to buy extensive company profiles from Dialog (http://www.dialog.com) that are replete with information extracted from a range of its business databases and arranged in a handsome, downloadable Microsoft Word document. How much? A mere $100 per company. |
The Motley Fool
July 20, 2006
Stephen D. Simpson |
Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching. |
Information Today
August 19, 2002
Paula J. Hane |
Dialog Expands SourceOne Document Delivery Service Dialog has announced its "re-entry into the document delivery market" with an expansion of its Dialog SourceOne service. Dialog has increased the number and diversity of sources from which articles and reports can be ordered, and has improved the delivery process for documents. |
The Motley Fool
January 25, 2007
Brian Lawler |
Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Information Today
February 18, 2002
Barbara Quint |
New Dialog E-journal Feature Links Database Citations to Full-Text Article Images Dialog Corp. has become the first of the traditional commercial online services to offer users full linking from citations appearing in abstract/index databases to electronic versions of the journals... |
Information Today
February 19, 2007
Tara Breton |
Elsevier Introduces Emscopes Database for Drug Information Emscopes is a more powerful product literature database (PLD) that is a directed at the specific needs of subscribing clients in pharmaceutical and biotech companies. |
Information Today
November 5, 2007 |
Thomson Scientific Adds EMBASE Classic to Dialog and DataStar The addition provides access to more than 25 years of archived life sciences data available for the first time in electronic format. |
Searcher
May 2003
Matthew McBride |
The Information Pricing Mousetrap The high cost of searching is the primary inhibition to developing more effective search habits for most users. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
Information Today
February 7, 2005
Marydee Ojala |
Dialog Divides into Sci-Tech/Intellectual Property and Business/News Parent company Thomson Corp.'s management looked at the various product lines within Dialog and decided they fell into two separate areas. |
Information Today
October 18, 2004
Barbara Quint |
Streaming Live News from Dialog The news feed agency launched a personalized service called Dialog Live News, which provides real-time, automated streaming of news reports from 2,300 sources. The service mainly covers business information, market conditions, economic indicators, SEC EDGAR reports, etc. |
The Motley Fool
October 23, 2006
Brian Lawler |
MGI's Anonymous Growth If there's a value stock in the pharma world, this may be it. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
Registered Rep.
March 1, 2005
David A. Twibell |
What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
June 11, 2007
Brian Lawler |
Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul. |
The Motley Fool
December 8, 2004
Alyce Lomax |
Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
InternetNews
July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. |
Information Today
December 1, 2003 |
NewsBreaks Dialog Launches Dialog API... STN Launches French and British Patent Databases... ProQuest Announces New Agreements... etc. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after. |
Information Today
July 23, 2013
Marydee Ojala |
ProQuest Gives Dialog a Makeover Dialog, the 40-year-old doyenne of online information, is getting a well-deserved -- and long overdue -- makeover as it transitions to a new platform designed to bring it into the modern world. |
The Motley Fool
August 12, 2011
David Williamson |
What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter? |
Information Today
May 6, 2014 |
ProQuest Acquires Pi2 ProQuest announced its acquisition of the U.K.-based Pi2, which provides information and literature management to biopharmaceutical companies. |
Bio-IT World
November 2005
Patrick R. Scanlon |
Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term. |
Information Today
April 1, 2002
Barbara Quint |
Gale Group, Dialog Announce Library Marketing Alliance Two Thomson Corp. subsidiaries, Gale Group and Dialog Corp., have announced that they will begin a comprehensive, long-term joint-marketing effort designed to reach the academic and public library markets worldwide... |
Information Today
June 19, 2000
Paula J. Hane |
Dialog Announces Info Pro Portal The Dialog Corporation, now a subsidiary of Thomson Corp., has announced a Web portal for professional searchers that provides customizable access to industry information and news and to Dialog's products and services. |
Information Today
October 22, 2001
Barbara Quint |
Changes at Dialog Dialog starts rollout of new connect-time pricing, completes simplification of sales contracts... |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions. |
Information Today
August 26, 2010
Paula J. Hane |
ProQuest Dialog Begins New Platform Rollout; New ProQuest Platform Begins Preview Period Since the acquisition of Dialog 2 years ago by ProQuest, customers of the Dialog and DataStar services have been keeping a close watch to see what would happen. |
Information Today
June 2001
Paula J. Hane |
Dialog CEO Optimistic About Opportunities Thomson Corp. purchased Dialog from its British owners on May 4, 2000, and in November named a seasoned Thomson executive as Dialog's new president and CEO. Now Roy M. Martin Jr. has had 6 months at the helm... |
Information Today
October 7, 2002
Barbara Quint |
Gale ReferenceLink Brings Dialog Back to Public/Academic Library Market Thomson Corp.'s Gale Group subsidiary has a strong presence in the public and academic library markets -- markets that Dialog Corp., another Thomson subsidiary, has generally abandoned for years. Dialog's data is now coming back, but will be supplied and supported by Gale. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
Information Today
February 9, 2004
Barbara Quint |
Dialog Choice Offers Flat-Fee Enterprise-Wide Subscription Pricing A new pricing initiative called Dialog Choice will offer unlimited access to selected content on Dialog at a fixed annual price. At this point, 40 information providers have agreed to put some 70 databases into the program. |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
Information Today
September 23, 2002
Paula J. Hane |
CSA Beefs Up Service, Will Remove Its Files from Dialog Searchers who logged on to Dialog Classic last week were greeted by a surprise announcement: The abstract databases from Cambridge Scientific Abstracts (CSA) will no longer be available through the Dialog and Dialog DataStar services. |
